Immunopotentiation of anticancer chemotherapy by<i>Candida albicans</i>, other yeasts and insoluble glucan in an experimental lymphoma model

Cassone, Antonio; Bistoni, Francesco; Cenci, Elio; Pesce, Caterina Delfina; Tissi, Luciana; Marconi, Pierfrancesco

doi:10.1080/00362178285380191

Cited by 11 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, there is evidence that β-glucans may modulate other conditions (cholesterol level, glucose tolerance, etc.). [ 20 - 22 ]. As it is mentioned above, many studies have reported the ability of pleuran to activate innate immunity with effects also on adaptive immunity, inducing humoral and cell-mediated immune responses.…”

Section: Discussionmentioning

confidence: 99%

Effects of Pleuran (Β–Glucan from Pleurotus Ostreatus) Supplementation on Incidence and Duration of COPD Exacerbations

Минов¹,

Bislimovska-Karadzhinska²,

Petrova³

et al. 2017

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND:1,3/1,6-β–glucans are recognised as immunomodulators in human and veterinary medicine for over 50 years.AIM:To assess the effects of pleuran (1,3/1,6-β–glucan from Pleurotus ostreatus) on incidence and duration of bacterial exacerbations in patients with COPD.METHODS:We performed an observational, non-randomized, open-label study including 32 COPD patients (Group D) in whom besides the recommended chronic treatment for the stable disease were administered supplement combination containing pleuran 100 mg, vitamin C 60 mg and zinc 5 mg once daily over a three month-period (Group 1). Also, an equal number of Group D COPD patients who besides the recommended treatment for stable disease received the supplement combination containing vitamin C 60 mg and zinc 5 mg once daily, matched to the study subjects of the Group 1 by sex and age served as control (Group 2).RESULTS:Over the study period 57 exacerbations (24 in the Group 1 and 33 in the Group 2) were documented. A mean number of exacerbations over the study period was significantly lower in the Group1 (0.7 ± 0.4) as compared to their mean number in the Group 2 (1.0 ± 0.6) (P = 0.0218). Furthermore, a mean duration of exacerbations expressed in days needed for cure or clinical improvement (i.e. complete resolution of symptoms or return of the symptoms to their baseline severity) in the Group 1 (6.7 ± 0.8 days) was significantly shorter than the mean duration of exacerbations in the Group 2 (7.4 ± 1.3 days) (P = 0.0118). There was not reported any adverse effect during the study period by study subjects from both examined groups.CONCLUSION:Our findings indicated that pleuran might impact the incidence and duration of bacterial exacerbations in patients with COPD. There is a need for further studies for more precise determination of the influence of pleuran on the course of COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Pleuran (Β–Glucan from Pleurotus Ostreatus) Supplementation on Incidence and Duration of COPD Exacerbations

Минов¹,

Bislimovska-Karadzhinska²,

Petrova³

et al. 2017

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…Finally, there is evidence that β-glucans may modulate other conditions (cholesterol level, glucose tolerance, etc.). [34], [35], [36]. However, the doses of pleuran for clinical use in both children and adults, as well as the duration of the treatment, are still not well defined.…”

Section: Discussionmentioning

confidence: 99%

Effects of Pleuran (β-glucan from Pleurotus ostreatus) Supplementation on Incidence and Duration of Bronchiectasis Exacerbations

Минов

Stoleski

Karadžinska-Bislimovska

et al. 2020

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Patients with non-cystic fibrosis bronchiectasis (BE) have frequent exacerbations that are causes of significant morbidity and sometimes mortality, and which it is desirable to prevent. AIM: We aimed to assess the effects of pleuran on the incidence and duration of exacerbations in patients with BE. METHODS: A prospective, observational, open-label, and active-controlled study was realized as a comparison of the frequency and duration of exacerbations between a group of patients with BE (30 patients, 14 males and 16 females, aged 44–72 years) who received a combination supplement containing pleuran 100 mg, Vitamin C 60 mg and zinc 5 mg over a 3-month period and a group of patients with BE (31 patients, 15 males and 16 females, aged 45–74 years) treated over a 3-month period with a combination supplement containing Vitamin C 60 mg and zinc 5 mg. RESULTS: Over the study period, altogether 46 exacerbations were documented (19 in the patients receiving pleuran and 27 in the patients who did not receive pleuran), nine of which required hospital treatment (four in the patients receiving pleuran [21.5%] and five in the patients who did not receive pleuran [18.6%]). The mean number of exacerbations over the study period was significantly lower in the patients receiving pleuran (0.6 ± 0.4) as compared to the mean number in the patients who did not receive pleuran (0.8 ± 0.3) (p = 0.0297). The mean duration of exacerbations, expressed in days, needed for cure or clinical improvement in the patients receiving pleuran (11.2 ± 1.7 days) was significantly shorter than that of exacerbations in the patients who did not receive pleuran (12.4 ± 1.3 days) (p = 0.0029). We found significantly lower incidence and significantly shorter duration of exacerbations in the patients with BE who received pleuran as compared to their incidence and duration in the patients with BE who did not receive pleuran. CONCLUSION: Our findings indicated a need for further investigations in this domain to define the possible role of pleuran in the prevention of BE exacerbations.

show abstract

“…Shortly afterwards, their effects against tumor development in experimental animals were also described (37) and finally glucans were reported to modulate other conditions (e.g., cholesterol levels, glucose tolerance) (38,39). …”

Section: Immunostimulatory Properties Of Glucansmentioning

confidence: 99%

Immunostimulatory properties and antitumor activities of glucans

Vannucci¹,

Křižan²,

Šíma³

et al. 2013

International Journal of Oncology

182

124

View full text Add to dashboard Cite

New foods and natural biological modulators have recently become of scientific interest in the investigation of the value of traditional medical therapeutics. Glucans have an important part in this renewed interest. These fungal wall components are claimed to be useful for various medical purposes and they are obtained from medicinal mushrooms commonly used in traditional Oriental medicine. The immunotherapeutic properties of fungi extracts have been reported, including the enhancement of anticancer immunity responses. These properties are principally related to the stimulation of cells of the innate immune system. The discovery of specific receptors for glucans on dendritic cells (dectin-1), as well as interactions with other receptors, mainly expressed by innate immune cells (e.g., Toll-like receptors, complement receptor-3), have raised new attention toward these products as suitable therapeutic agents. We briefly review the characteristics of the glucans from mycelial walls as modulators of the immunity and their possible use as antitumor treatments.

show abstract

Immunopotentiation of anticancer chemotherapy byCandida albicans, other yeasts and insoluble glucan in an experimental lymphoma model

Cited by 11 publications

References 16 publications

Effects of Pleuran (Β–Glucan from Pleurotus Ostreatus) Supplementation on Incidence and Duration of COPD Exacerbations

Effects of Pleuran (Β–Glucan from Pleurotus Ostreatus) Supplementation on Incidence and Duration of COPD Exacerbations

Effects of Pleuran (β-glucan from Pleurotus ostreatus) Supplementation on Incidence and Duration of Bronchiectasis Exacerbations

Immunostimulatory properties and antitumor activities of glucans

Contact Info

Product

Resources

About